Small Lymphocytic Lymphoma Clinical Trials

266 clinical trials for Small Lymphocytic Lymphoma across international registries, including 65 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients. — RECRUITING · PHASE1
• Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study — RECRUITING · PHASE3
• A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies — RECRUITING · PHASE1
• Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL — RECRUITING · PHASE2
• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — RECRUITING · PHASE3
• A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) — RECRUITING · PHASE3
• A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — RECRUITING · PHASE3
• Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab — RECRUITING · PHASE2
• A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies — RECRUITING · PHASE1
• Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) — RECRUITING · PHASE1
• A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) — RECRUITING · PHASE2
• Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) — RECRUITING
• A Long-term Extension Study of PCI-32765 (Ibrutinib) — RECRUITING · PHASE3
• Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib — RECRUITING · PHASE1
• A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — RECRUITING · PHASE3
• Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias — RECRUITING · PHASE1
• Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: — RECRUITING
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Combating Cancer-Related Fatigue: A Personalized Supportive Care Program — RECRUITING · NA
• Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• 64Cu-LLP2A for Imaging Hematologic Malignancies — RECRUITING · PHASE1
• A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. — RECRUITING · PHASE1
• Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma — RECRUITING · PHASE2
• Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL — RECRUITING · PHASE2
• Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial — RECRUITING · PHASE2
• Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma — RECRUITING
• Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL — RECRUITING · PHASE2
• Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies — RECRUITING · PHASE1
• Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial — RECRUITING · PHASE2
• Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi — RECRUITING · PHASE2
• Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia — RECRUITING · PHASE2
• Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) — RECRUITING · PHASE1
• Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia — RECRUITING · PHASE2
• Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia — RECRUITING · PHASE2
• Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL — RECRUITING · PHASE2
• Study of Epcoritamab as a Consolidation Therapy in CLL/SLL — RECRUITING · PHASE2
• A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — RECRUITING · PHASE2
• Mosunetuzumab for CLL MRD Clearance — RECRUITING · PHASE1
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Zanubrutinib and Venetoclax in CLL (ZANU-VEN) — RECRUITING · PHASE2
• A PHASE III, RANDOMISED, OPEN-LABEL, MULTICENTRE, STUDY OF SUROVATAMIG AS CONSOLIDATION THERAPY VERSUS OBSERVATION AFTER FIRST-LINE INDUCTION THERAPY IN PARTICIPANTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA OR SMALL LYMPHOCYTIC LYMPHOMA WITH UNMUTATED IGHV (SOUNDTRACK-C1) — RECRUITING · PHASE3
• Two Step Haplo With Radiation Conditioning — RECRUITING · PHASE2
• A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — RECRUITING · PHASE2
• Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment — RECRUITING

Refine this search